Guzmán PMG, Saeb LM

Language: Spanish
References: 11
Page: s84-90
PDF size: 371.86 Kb.

ABSTRACT

The SARS-CoV-2 virus pandemic was presented as a disease with great morbidity and mortality. Since then, the race for the production of a vaccine that would prevent serious disease and reduce transmission began. Numerous laboratories joined the effort and multiple platforms were developed: mRNA, viral vector, viral protein subunits, DNA, live attenuated viruses, etcetera. Only the first two have been applied in vaccination campaigns. However, none is exempt from causing side effects, which can be immediate and/or late. These effects are explained by the direct release of histamine and vasoactive peptides mediated by IgE or activation of the alternative complement pathway. Late lesions are related to the deposition of immune complexes, vascular damage and infiltration by inflammatory cells in the skin, at the site of the vaccine application or remotely, causing subacute dermatitis or purpuric plaques. So far, over 50 years of age have been vaccinated in Mexico, a population that is under multiple treatments and in whom toxic intermediate metabolites, the viral effect or the mechanism of action of the drugs themselves can act together to develop complex clinical pictures

REFERENCES

1. Covid. [11 Mayo 2021 14.52 pm] live update: https://www.worldometers.info

2. US Department of Health and Human Services/Centers for Diseases Control and Prevention. Allergic Reactions Including Anaphyaxis after reciept of the first dose of Pfizer-BioNTech COVID- Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases COVID-19 Vaccine United States. MMWR. 2021; 70 (2): 46-51.

3. Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020; 288: 198114. doi: org./10-1016/j.virusres.2020.198114.

4. Worm M, Bauer A, Wedi B, Treudler R, Pfuetzner W, Brockow K et al. Practical recommendations for the allergological risk assessment of the COVID-19 vaccination- a harmonized statement of allergy centers in Germany. Allergol Select. 2021; 5: 72-76. doi: 105414/ALX02225E.

5. Ring J, Worm M, Wollenberg A, Thyssen JP, Jakob T, Kilmek L et al. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases-practical recommendations. A position statement of ETFAD with external experts. J Eur Acad Dermatol Venereol. 2021; 35 (6): e362-e365. doi: 10.1111/jdv.17237.

6. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021; 85 (1): 46-55. Available in: https://doi.org/10.1016/j.jaad.2021.03.092

7. Klimek L, Novak N, Cabanillas B, Jutel M, Bousquet J, Akdis CA. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation. Allergy. 2021;3:10.1111/all.14794. doi: 10.1111/JOCD14794.

8. Johnston MS, Galan A, Watsky KL, Little AJ. Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine: a case series. JAMA Dermatol. 2021; 157 (6): 716-720. doi: 10.1001jamadermatol.20211214.

9. Tammaro A, Magri F, Chello C. Local skin reaction to the AZD1222 vaccine in patient who survived COVID-19. J Cosmet Dermatol. 2021. Available in: https://doi.org/10.1111/jocd.14205

10. Lam M, Egail M, Bedlow AJ, Tso S. Ribonucleic acid (RNA) COVID-19 vaccine associated cutaneous adverse drug events: a case series of two patients. Clin Exp Dermatol. 2021. Available in: https://doi.org/10.1111/ced.14673021

11. Banerji A, Wickner PG, Saff R, Stone CA, Robinson LB, Long AA et al. mRNA Vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allerg Clin Immunol Pract. 2021; 9 (4): 1423-1437. Available in: https://doi.org/10.1016/j.jaip.2020.12.047